Creation of a Biobank of Biological Samples From Patients With Malignant Hypertension

Launched by CENTRE HOSPITALIER DE PAU · Oct 3, 2024

Keywords

ClinConnect Summary

This clinical trial, called the HAMA bank, is focused on creating a collection of biological samples from patients who have malignant hypertension, which is a severe form of high blood pressure that can lead to serious health problems. The goal of this study is to better understand the causes of malignant hypertension and to find new ways to diagnose and treat it. The samples collected will be stored in a special biobank, which is like a library for biological materials, to help researchers study the disease more effectively.

To participate in this trial, you need to be part of the HAMA cohort and have a diagnosis of malignant hypertension. This means you have very high blood pressure that is causing significant damage to your body, especially your eyes. If you are currently on chronic dialysis or choose not to participate, you won’t be eligible for this study. Participants can expect to provide biological samples, which will help advance research in this area. This initiative is not yet recruiting patients, but it aims to create a valuable resource for future medical advancements related to malignant hypertension.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * patients included in the HAMA cohort with the following critera :
• • Malignant hypertension according to the classic definition (Severe hypertension associated with severe hypertensive retinopathy)
• • Severe hypertension associated with acute target organ damage due to high blood pressure
• Exclusion Criteria:
• • Refusal to participate to the substudy " HAMA bank "
• • patient on chronic dialysis